John Glasspool built his career in cardiovascular and metabolic medicine, having led that area at Novartis before helping launch Anthos with Blackstone Life Sciences, focused for years on tough problems like thrombosis and anticoagulation where bleeding risk still limits treatment, and later served as President of European Biopharmaceutical Enterprises while at Novartis Vaccines. He brings a distinct outlook to healthcare and biotech, talking about treating the whole person rather than just a diagnosis, viewing home-based technology as a way to bring back the personal connection of old-time house calls, planning backward from the end goal in manufacturing to catch problems early, treating outside partners as true partners rather than vendors, and being trusted to moderate high-level policy discussions like the BIOSECURE Act with BIO's chief scientific officer.